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Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array. Recent studies re-
vealed that the FAT1 expression is associated with disease activity of FSHD, and the FAT1 alterations result in myopathy with a 
FSHD-like phenotype. We describe a 59-year-old woman with both contracted D4Z4 repeat units and a FAT1 mutation. Shoulder 
girdle muscle weakness developed at the age of 56 years, and was followed by proximal leg weakness. When we examined her at 
59 years of age, she displayed asymmetric and predominant weakness of facial and proximal muscles. Muscle biopsy showed in-
creased variation in fiber size and multifocal degenerating fibers with lymphocytic infiltration. Southern blot analysis revealed 8 
D4Z4 repeat units, and targeted sequencing of modifier genes demonstrated the c.10331 A>G variant in the FAT1 gene. This FAT1 
variant has previously been reported as pathogenic variant in a patient with FSHD-like phenotype. Our study is the first report of 
a FAT1 mutation in a FSHD1 patient, and suggests that FAT1 alterations might work as a genetic modifier. 
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INTRODUCTION
Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is 
a common muscular dystrophy characterized by an asymmet-
ric descending progression starting in the face or shoulder-
girdle muscles. FSHD1 is caused by contraction of the D4Z4 re-
peat array on chromosome 4q35 to a size of 1 to 10 units. The 
clinical severity of FSHD1 is inversely correlated with D4Z4 
repeat units, and many patients with 7 to 10 D4Z4 repeat units 
have mild disease activity and remain nonpenetrant.1,2 Addi-
tionally, the D4Z4 repeat of 8−10 units is found in 1−3% of the 
healthy control populations.3 However, the repeat units are 
not always predictive for clinical severity, and patients with 8 
to 10 D4Z4 repeat units occasionally revealed early symptom 
onset and severe clinical phenotype.1 Actually, the SMCHD1 
and DNMT3B genes have recently been identified as genetic 
modifiers in FSHD1.4,5 
The FAT1 gene is located on chromosome 4q35 proximal to 
the D4Z4 repeat array. The FAT1 mutations are linked to vari-
ous diseases including schizophrenia, bipolar disorder, and 
cancer. It is known that this gene influences muscle pattern-
ing, regionalized muscle wasting, and adult muscle fiber func-
tions.6 Furthermore, faulty regulation of the FAT1 expression 
was observed in FSHD1 muscle tissue, and mutations in FAT1 
were found in patients with a FSHD-like phenotype.7,8
To identify the existence of a genetic modifier in Korean pa-
tients with FSHD1, we performed targeted sequencing of 
SMCHD1, DNMT3B, and FAT1 genes in patients with 8−10 
D4Z4 repeat units. Then, we found that one patient had both 8 
D4Z4 repeat units and a FAT1 mutation.
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CASE REPORT
A 59-year-old woman in the MF1147 family presented to our 
neurologic clinic with proximal muscle weakness. She did not 
have a family history of any neuromuscular disorders. She first 
had gait disturbance and low back pain since her twenties. 
She felt weakness in shoulder girdle muscles at the age of 56 
years. Then, she had had difficulty to rise from the floor since 
the age of 57 years. When we examined her at 59 years, she 
could walk independently. She displayed asymmetric and 
predominant weakness of shoulder and hip girdle muscles. 
Additionally, she had facial muscle weakness. She did not ex-
hibit sensory deficits and joint contractures. Her serum cre-
atine kinase level was 140 IU/L (reference value: <135 IU/L). 
Needle electromyography was compatible with generalized 








Fig. 1. Histopathological results and T1-weighted MR images of whole body. (A) Hematoxylin and eosin (H-E) staining revealed increased variation in 
fiber size and multifocal degenerating fibers with lymphocytic infiltration. (B) Modified Gomori-trichrome (GT) staining did not reveal any intracyto-
plasmic inclusions and subsarcolemmal depositions. (C) Staining with reduced nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-tr) 
showed mild disorganization of intermyofibrillar network. (A, H-E stain, ×200; B, modified GT stain, x100; and C, NADH-tr stain, ×100). (D-G) T1-weight-
ed MR images of whole body. (D) At the upper arm level, biceps brachii muscles were shown to be predominantly affected on the right side (white 
arrows). (E) At the abdominal level, both abdominal (black arrow heads) and paraspinal (black arrows) muscles were found to be totally replaced by 
fat tissues. (F) At the thigh levels, semitendinosus, semimembranosus, biceps femoris, vastus medialis, and vastus intermedius muscles were totally 
replaced by the fat tissue. Rectus femoris muscles were shown to be severely affected on the right side (white arrow heads). (G) At the calf level, bi-
lateral soleus muscles were shown to be predominantly affected.
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(Fig. 1A-C). Hematoxylin and eosin staining revealed in-
creased fiber size variability, increased endomysial fibrosis, 
and multifocal degenerating fibers with lymphocytic infiltra-
tion. Modified Gomori-trichrome staining did not demon-
strate any intracytoplasmic inclusions and subsarcolemmal 
depositions. Staining with reduced nicotinamide adenine di-
nucleotide-tetrazolium reductase showed mild disorganiza-
tion of intermyofibrillar network. Whole body MR images 
were performed (Fig. 1D-G). At the upper arm level, T1-weight-
ed MR images demonstrated predominant fatty replacement 
of right biceps brachii muscle. At the abdominal level, both 
abdominal and paraspinal muscles were found to have been 
totally replaced by fat tissues. At the thigh levels, semitendino-
sus, semimembranosus, biceps femoris, vastus medialis, and 
vastus intermedius muscles were shown to be totally replaced 
by the fat tissue. Rectus femoris muscle on the right side was 
severely affected. At the calf level, the MR image revealed bi-
lateral soleus muscles predominantly affected.
Based on these clinical, pathological, and radiological pre-
sentation, we assumed that her disease was FSHD1. To deter-
mine the size of the D4Z4 repeat arrays, we performed South-
ern blot analysis and found 8 D4Z4 repeat units, therefore, she 
was diagnosed with FSHD1. Subsequently, we performed tar-
geted-next generation sequencing of modifier genes includ-
ing the SMCHD1, DNMT3B, and FAT1 genes to find the exis-
tence of a genetic modifier in Korean patients with FSHD1. 
Targeted sequencing was performed in 9 unrelated patients. 
All patients had asymmetric descending progression starting 
in the face or shoulder-girdle muscles and carried a contract-
ed allele from 8 to 10 D4Z4 repeat units. Finally, we identified 
previously reported c.10331 A>G (p.N3444S) variant in FAT1 
gene in the present case. This FAT1 variant was previously re-
ported as a mutation in a myopathy patient who had a FSHD-
like phenotype but did not have the contraction of the D4Z4 
repeat units.8
DISCUSSION
In the present study, we identified a FAT1 mutation in a Kore-
an patient with the shortening. The c.10331 A>G FAT1 variant 
has rarely been reported in dbSNP142 and the Exome Variant 
Server with allele frequencies of 0.00008. However, in vitro 
functional study demonstrated that this variant induced par-
tial alteration of splicing by breaking an exonic splicing en-
hancer.8 Therefore, c.10331 A>G variant in the FAT1 gene is a 
pathogenic variant and influenced clinical phenotype of the 
present patient. 
The FAT1 gene encodes a single pass transmembrane pro-
tein with the extracellular portion consisting of 34 cadherin re-
peats, five EGF-like domains and a laminin-G like domain. This 
protein belongs to the FAT cadherin superfamily and influ-
ences multiple biological activities, including smooth muscle 
cell motility, actin accumulation, cell polarity, and migrating 
muscle precursors.9-12 Recent studies demonstrated that the 
FAT1 expression is closely related with disease onset and the 
alterations in FAT1 gene cause FSHD-like myopathy.7,8 Howev-
er, the pathogenic mechanism of FAT1 mutations in myopa-
thy remains unclear.
The present case revealed facial diplegia, asymmetric de-
scending progression, and lymphocytic infiltration. It was com-
patible with FSHD1, but we could not find any add-on effects 
of FAT1 alterations. It is probably because that the clinical pre-
sentation of FAT1 myopathy closely resembles that of FSHD1. 
Previous study demonstrated predominant involvement of fa-
cial, scapular, and humeral muscles and progression of the 
disease toward the lower limbs in patients with FAT1 muta-
tions.8 These findings are typical clinical features of FSHD1. 
We initially planned neurological examination and segrega-
tion study of the D4Z4 contraction and the FAT1 mutation in 
the family. However, the patient and her family members re-
fused further evaluation and genetic testing. Further studies are 
needed to identify the role of a genetic modifier of FAT1 gene 
in FSHD1. 
In conclusion, our study is the first report of coexistence of 
the contracted D4Z4 repeats and FAT1 mutation in a FSHD1 
patient.
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